In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis AG

www.novartis.com

Latest From Novartis AG

Merck/Bayer’s Vericiguat Outcomes Data Less Impressive On Fuller Disclosure

Efficacy seen in reducing hospitalization in high-risk heart failure patients, but not in reducing the risk of cardiovascular death. Analysts say this portends a more niche opportunity for vericiguat.

Clinical Trials Comparative Effectiveness

Biopharma COVID-19 Collaborations May Avoid Antitrust Hurdles, FTC And DOJ Suggest

FTC and DoJ issue guidance for businesses working together to tackle coronavirus pandemic; BIO is 'pleased' they intend to help facilitate critical partnerships.

Coronavirus COVID-19 Enforcement

Narasimhan's Culture Club On Song At Novartis

Taking over at the Swiss firm as CEO in 2018, Vas Narasimhan set about creating an "inspired, curious and unbossed organization." Two years on, he has put the spotlight on several initiatives that are up and running on a number of fronts to achieve that goal.

Commercial Companies

Novartis CEO Backs Malaria Drug Against COVID-19

A coronavirus vaccine is some way off and until then, Vas Narasimhan, head of Novartis, is thinking that of the drugs being repurposed to treat COVID-19, hydroxychloroquine looks best places to provide the quickest benefit.

Coronavirus COVID-19 Clinical Trials
See All

Company Information

UsernamePublicRestriction

Register